Literature DB >> 21788469

Susceptibility of Pneumocystis to echinocandins in suspension and biofilm cultures.

Melanie T Cushion1, Margaret S Collins.   

Abstract

The targeted inhibition of cyst but not trophic development by anidulafungin, caspofungin, and micafungin on Pneumocystis murina and Pneumocystis carinii in rodent models of Pneumocystis carinii pneumonia (PCP) was recently reported by us (M. T. Cushion et al., PLoS One 5:e8524, 2010). To better understand the effects of echinocandins on P. carinii, the same three compounds were evaluated in standard suspension and biofilm cultures supplemented with various concentrations of sera using the measurement of ATP as the indicator. In suspension cultures with 1 and 5% serum, anidulafungin was the most active compound but 10 and 20% serum abrogated the efficacy of all three echinocandins. Established biofilm cultures that included both the nonadherent and adherent phases were more resistant to micafungin than caspofungin regardless of serum concentration, while anidulafungin had significant activity at 1 and 5% serum concentrations. Nascent biofilms were mostly affected by anidulafungin in 1 and 5% serum, but none of the compounds showed significant activity in 20% serum. We show for the first time that (i) echinocandins differ in their abilities to deplete the ATP of Pneumocystis in biofilms and in suspension cultures, (ii) this variability mostly reflected the reported efficacies in animal models of infection, and (iii) high serum levels decreased the anti-Pneumocystis activities of the echinocandins in both in vitro systems.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21788469      PMCID: PMC3186961          DOI: 10.1128/AAC.00017-11

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  36 in total

Review 1.  Pneumocystis carinii pneumonia with oral candidiasis after infliximab therapy for Crohn's disease.

Authors:  Nirmal Kaur; Thomas C Mahl
Journal:  Dig Dis Sci       Date:  2004-09       Impact factor: 3.199

2.  Effects of atovaquone and diospyrin-based drugs on the cellular ATP of Pneumocystis carinii f. sp. carinii.

Authors:  M T Cushion; M Collins; B Hazra; E S Kaneshiro
Journal:  Antimicrob Agents Chemother       Date:  2000-03       Impact factor: 5.191

3.  In vitro pharmacodynamic properties of three antifungal agents against preformed Candida albicans biofilms determined by time-kill studies.

Authors:  Gordon Ramage; Kacy VandeWalle; Stefano P Bachmann; Brian L Wickes; José L López-Ribot
Journal:  Antimicrob Agents Chemother       Date:  2002-11       Impact factor: 5.191

4.  In vitro activity of caspofungin against Candida albicans biofilms.

Authors:  Stefano P Bachmann; Kacy VandeWalle; Gordon Ramage; Thomas F Patterson; Brian L Wickes; John R Graybill; José L López-Ribot
Journal:  Antimicrob Agents Chemother       Date:  2002-11       Impact factor: 5.191

5.  Standardized method for in vitro antifungal susceptibility testing of Candida albicans biofilms.

Authors:  G Ramage; K Vande Walle; B L Wickes; J L López-Ribot
Journal:  Antimicrob Agents Chemother       Date:  2001-09       Impact factor: 5.191

6.  Biofilm formation by the fungal pathogen Candida albicans: development, architecture, and drug resistance.

Authors:  J Chandra; D M Kuhn; P K Mukherjee; L L Hoyer; T McCormick; M A Ghannoum
Journal:  J Bacteriol       Date:  2001-09       Impact factor: 3.490

7.  Influence of human sera on the in vitro activity of the echinocandin caspofungin (MK-0991) against Aspergillus fumigatus.

Authors:  T Chiller; K Farrokhshad; E Brummer; D A Stevens
Journal:  Antimicrob Agents Chemother       Date:  2000-12       Impact factor: 5.191

8.  Association of chronic obstructive pulmonary disease severity and Pneumocystis colonization.

Authors:  Alison Morris; Frank C Sciurba; Irina P Lebedeva; Andrew Githaiga; W Mark Elliott; James C Hogg; Laurence Huang; Karen A Norris
Journal:  Am J Respir Crit Care Med       Date:  2004-04-29       Impact factor: 21.405

Review 9.  In vitro antifungal activities of anidulafungin and micafungin, licensed agents and the investigational triazole posaconazole as determined by NCCLS methods for 12,052 fungal isolates: review of the literature.

Authors:  Ana Espinel-Ingroff
Journal:  Rev Iberoam Micol       Date:  2003-12       Impact factor: 1.044

Review 10.  Sterol biosynthesis and sterol uptake in the fungal pathogen Pneumocystis carinii.

Authors:  Tiffany M Joffrion; Melanie T Cushion
Journal:  FEMS Microbiol Lett       Date:  2010-10       Impact factor: 2.742

View more
  19 in total

Review 1.  Candida albicans Biofilms and Human Disease.

Authors:  Clarissa J Nobile; Alexander D Johnson
Journal:  Annu Rev Microbiol       Date:  2015       Impact factor: 15.500

2.  Pneumocystis jiroveci pneumonia in patients with non-Hodgkin's lymphoma after Rituximab-containing regimen: two cases of report and literature review.

Authors:  Xu-Qin Jiang; Lei Fang; Xiao-Dong Mei; Xiao-Jing Wang; Ming-Hong Bao
Journal:  J Thorac Dis       Date:  2013-08       Impact factor: 2.895

Review 3.  Analysis of current antifungal agents and their targets within the Pneumocystis carinii genome.

Authors:  Aleksey Porollo; Jaroslaw Meller; Yogesh Joshi; Vikash Jaiswal; A George Smulian; Melanie T Cushion
Journal:  Curr Drug Targets       Date:  2012-11       Impact factor: 3.465

4.  Efficacy of Trimethoprim-Sulfamethoxazole in Combination with an Echinocandin as a First-Line Treatment Option for Pneumocystis Pneumonia: A Systematic Review and Meta-Analysis.

Authors:  Hideo Kato; Mao Hagihara; Nobuhiro Asai; Takumi Umemura; Yuichi Shibata; Jun Hirai; Yuka Yamagishi; Takuya Iwamoto; Hiroshige Mikamo
Journal:  Antibiotics (Basel)       Date:  2022-05-26

5.  Evidence for a Pneumocystis carinii Flo8-like transcription factor: insights into organism adhesion.

Authors:  Theodore J Kottom; Andrew H Limper
Journal:  Med Microbiol Immunol       Date:  2015-07-28       Impact factor: 3.402

Review 6.  A Molecular Window into the Biology and Epidemiology of Pneumocystis spp.

Authors:  Liang Ma; Ousmane H Cissé; Joseph A Kovacs
Journal:  Clin Microbiol Rev       Date:  2018-06-13       Impact factor: 26.132

7.  Site-Directed Mutagenesis of the 1,3-β-Glucan Synthase Catalytic Subunit of Pneumocystis jirovecii and Susceptibility Assays Suggest Its Sensitivity to Caspofungin.

Authors:  A Luraschi; S Richard; P M Hauser
Journal:  Antimicrob Agents Chemother       Date:  2018-11-26       Impact factor: 5.191

8.  Chloroquine Analogues as Leads against Pneumocystis Lung Pathogens.

Authors:  Ana Gomes; Ricardo Ferraz; Lauren Ficker; Margaret S Collins; Cristina Prudêncio; Melanie T Cushion; Cátia Teixeira; Paula Gomes
Journal:  Antimicrob Agents Chemother       Date:  2018-10-24       Impact factor: 5.191

Review 9.  Investigational Agents for the Treatment of Resistant Yeasts and Molds.

Authors:  Garret T Seiler; Luis Ostrosky-Zeichner
Journal:  Curr Fungal Infect Rep       Date:  2021-05-28

Review 10.  The Persistent Challenge of Pneumocystis Growth Outside the Mammalian Lung: Past and Future Approaches.

Authors:  Melanie T Cushion; Nikeya Tisdale-Macioce; Steven G Sayson; Aleksey Porollo
Journal:  Front Microbiol       Date:  2021-05-20       Impact factor: 5.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.